|
|
||||||||
REVIEW ARTICLE |
Address correspondence to Russell G. Gamber, DO, Department of Manipulative Medicine, University of North Texas Health Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX 76107-2644.E-mail: rgamber{at}hsc.unt.edu
Despite the value that osteopathic manipulative medicine (OMM) may offer to healthcare consumers in a managed care, evidence-based healthcare system, very little research has been published on the cost-effectiveness of osteopathic manipulative treatment compared with other treatment modalities. The authors searched MEDLINE and OSTMED for English-language articles published between January 1966 and June 2002 using the key terms cost-effectiveness, osteopathic medicine, workers' compensation, hospital length of stay, healthcare providers, and manipulative medicine. The authors then extended their search by reviewing the reference lists provided in the articles initially identified as relevant by these databases. The purpose, methods, findings, and conclusions of each study were evaluated for how the cost-effectiveness of OMM was analyzed. The authors conclude that the osteopathic medical profession needs to conduct and publish research that is consistent with current practices in the conventional medical literature.
Osteopathic manipulative medicine is a medical specialty unique to osteopathic physicians. Among the general public and even among some healthcare providers, this specialty is not well understood. For example, few healthcare consumers or professionals know that osteopathic physicians (DOs) are fully licensed physicians, with the same education, training, and residency requirements as allopathic physicians (MDs), but with additional specialty training in manual medicinethough this is only one of the many features that distinguish DOs from MDs. Experience tells us that healthcare consumers are generally unclear about differences between osteopathic manipulative medicine and other forms of body-based manual therapies, such as chiropractic care.
Although manual therapies exist in other professions, OMT is the term used to describe the specific set of techniques osteopathic physicians use to treat patients' musculoskeletal complaints as well as other dysfunctions and disorders.
Members of the chiropractic profession and healthcare insurance carriers have conducted studies comparing the costs of healthcare services provided by chiropractors with those provided by osteopathic physicians and allopathic physicians.14 Some of these studies used existing data from state workers' compensation claims to compare costs and outcomes by the type of healthcare services used.14 Other researchers analyzed case studies to compare the costs of ineffective traditional medical treatment with subsequent effective OMM treatments.5,6 Although most OMM treatment efficacy studies have not included direct measures of cost in the design, some researchers have used proxy variables or measurements that permit the imputation of costs.616
These imputed measures of cost include, for example, "effort invested by the provider," "hospital length-of-stay," or "time lost from work."3 However, these measures are somewhat imprecise proxies for actual direct and indirect cost data. These variables are sometimes called "imputed costs" because they are not actual expenditures or costs; rather, a dollar value is imputed to them. Experienced statisticians and health services researchers caution against using outcome variables that can only be assumed as associated with actual costs to draw inferences on real cost-effectiveness.17
In the osteopathic medical literature, we found few studies that include indirect measures of cost,6,9,15 and we believe this study to be the only systematic review of the few that were identified.
Socially responsible healthcare coverage policies and well-informed consumers depend on reliable information about the cost of healthcare services, especially when the clinical outcomes may be the same. The osteopathic medical profession should be taking steps to provide valid research findings to patients, providers, insurance carriers, and policymakers about the costs of OMM, both as an alternative to other medical treatments and as an adjunctive treatment to improve outcomes of standard care.
For the analysis in this paper, we focused on available published literature and reports of studies that claimed to measure healthcare costs and specifically included OMM or osteopathic physicians. These articles represent the current body of information on the cost-effectiveness of OMM. We analyzed this information with consideration for how future OMM cost-effectiveness analysis might be designed and conducted. Considerations included, for example, whether the researchers asked prospective cost questions, precisely defined the source and elements for their cost data, or collected direct measures of cost in a rigorously controlled design.
In this paper, we describe existing information and suggest how future OMM cost-effectiveness analysis might better inform economic and practice policies on healthcare.
| Methods |
|---|
|
|
|---|
We evaluated the purpose, methods, findings, and conclusions of each report to discuss their contributions to the literature about the cost-effectiveness of OMM. We included peer-reviewed journal articles, nonpeer-reviewed journal articles, and government reports.
Studies excluded from our review include those that did not (1) identify, define, and refer in the conclusions to specific direct, indirect, or imputed measures of cost associated with OMM, or (2) specifically identify osteopathic physicians as a study group. We included only published results and papers that specifically discussed insights on the cost of OMM compared with standard medical care.
The healthcare literature has evolved in recent decades to include a substantial body of quality cost-effectiveness analysis. Standards and criteria for cost-effectiveness analysis that are generally accepted in the conventional medical literature have been developed but are also not yet well established.17 These standards and criteria should be adopted and adapted by osteopathic medical researchers and clinicians attempting to measure the cost-effectiveness of OMM. Any study of medical cost-effectiveness and cost benefits should measure the "opportunity cost" of resources used in the provision of healthcare services.17 For example, resources, or factors of production, need to be identified, defined, and valued at competitive market rates in practice and certainly in published reports. Wage and benefit rates for labor inputs or prices for nonlabor inputs are commonly used to measure market value, but some markets are sufficiently uncompetitive so as not to require alternative measurement approaches.
The physician service market is one example where Resource-Based Relative Value Scales (RBRVS)18 are sometimes used. Healthcare cost studies often include direct medical costs and other indirect costs, such as the lost output of labor, time lost from work, or the cost of patient transportation. Although some of these indirect costs are borne by consumers of healthcare services and not directly by the healthcare sector, they are true economic costs and should be included in cost-effectiveness analysis to adhere to a higher standard of research for this type of study. In this way, all costs and benefits would be accounted for, regardless of their distribution.
| Results |
|---|
|
|
|---|
Some articles that had a stated purpose of measuring cost-effectiveness did not actually include any cost data. We included these, however, because of the prevalent tendency of researchers to "assume" (by imputing costs) that certain outcomes would logically have some relationship to the cost of care. These values are used as proxy variables (eg, length of hospital stay).
To emphasize the distinction between measures of direct cost and proxy variables, we grouped the studies according to whether they used actual15,1922 or imputed614 cost information. Table 1 provides a summary of the scope, design, and methods for each source document (eg, direct cost variables, indirect/imputed cost variables) in this paper.
|
Studies Using Direct Cost Variables
Nine published reports that used a direct measure of treatment costs or
social costs of the health condition being studied were
identified.15,1922
Six reports used existing workers' compensation claims data to examine or
describe the cost of spine-related injuries and treatment by type of
provider.14,19,21
Two reports used mixed models for the
research.7,10
|
|
|
|
The first of these four studies, published in JAOA in 2002, used the MOS [Medical Outcomes Study] 36-Item Short-Form Health Survey (SF-36)26 to interview patients receiving OMT in a clinic (N=185).13 Compared with patients in the normal reference range for SF-36 scores, patients referred to specialists for OMT had higher scores for pain, lower scores for quality of life, and higher scores for severity of physical limitations. The authors13 conclude from these findings that early detection and treatment of musculoskeletal conditions might prevent chronic debilitating conditions and reduce the deleterious effects on these patients' quality of life. The authors13 further suggest that these patients may indeed suffer more pain, have a lower quality of life, and experience more physical limitations than average because there is some evidence in the literature cited that individuals with chronic musculoskeletal problems feel marginalized and stigmatized in their experiences with other healthcare providers. The study did not measure patients' health perceptions after receiving OMT, however. Imputed costs in this study are associated with early detection preventing chronic disability.13
The second of these four studies, another 2002 JAOA paper, uses a 45-item questionnaire adapted from the Patient Satisfaction Questionnaire27 to survey patients in an ambulatory OMT clinic (N=459).14 As part of the inclusion criteria for this study, patients had to have received OMT at least twice previously. Although these patients self-reported poor health, 72% of them were very satisfied with the healthcare they received. Researchers examined the data for any relationship between pain and mobility.
Survey respondents reported a significant decline in pain and a significant increase in mobility (P<.001) after receiving OMT. Researchers also reported a significant, positive relationship between patient satisfaction and patients' perceptions of the efficacy of OMT (P<.001), and a significant inverse relationship between pain and overall patient satisfaction (P<.001). From the results of the survey, researchers suggested that OMT would be cost-effective, but despite its potential for cost savings through reduced pain and improved mobility, access to OMT is limited by many health insurance plans.14
In the last two of these four studies, researchers suggest that costs can be associated with improved functioning and ability to care for oneself or perform daily tasks.15,16 Both JAOA studies used strong research designs for small pilot studies but did not collect cost data.15,16
In the first 2002 JAOA study under review, researchers analyzed patient responses to survey questions about pain, response to treatment, activities of daily living (ADLs), and symptoms of depression in four experimental groups of women (N=24) diagnosed with fibromyalgia syndrome.15 The four groups were as follows: (1) OMT only, (2) OMT and education on fibromyalgia syndrome, (3) moist heat only, and (4) standard medication only. This study found that the patients receiving OMT improved their attitude toward treatment and improved in their ability to perform daily tasks. Patients receiving OMT also reported higher pain thresholds, indicating a reduced sensitivity to pain. Patients in the "moist heat" and "medication only" groups reported increased feelings of well being. The authors suggested that because the nonOMT groups reported "feeling better" despite no "handson" treatment, this reduces the chance that improvements reported by OMT group subjects might be confounded by the physicianpatient interaction factor. In that JAOA study, the researchers "impute" cost-effectiveness by suggesting that improved daily functioning and reduced use of pain medication can be tied to a social or economic cost.15
The final study in this group of four imputed-cost studies was also published in JAOA in 2002 and measured improvements in ADLs in elderly patients with diagnosed medical conditions that severely limit range of motion in one or both shoulder joints. Subjects were randomly assigned to OMT or sham manipulative treatment groups (N=29).16 At six weeks poststudy follow-up, only those subjects who received OMT continued to have improved range of motion. The range of motion for the sham manipulative treatment group, however, had sharply declined to below study baseline levels. Although both study groups reported a decrease in pain levels during the treatment phase of the study and an increase in pain at six weeks poststudy follow-up, the rate of increase for pain scores was almost two times greater for the control group than for the OMT group. Imputed costs were associated with avoidance of long-term, chronic rehabilitative care.16
| Comment |
|---|
|
|
|---|
Clinical outcome studies that suggested OMT was more cost-effective than other services also did not collect direct cost data. Studies that included both clinical outcomes data and some estimate of cost based on available information (eg, salaries, billing data) unfortunately either had incomplete data or did not clearly and operationally define cost variables.
Generally speaking, cost-effectiveness studies can be expected to produce one or more of the observed results displayed in Table 4. If treatment X produces better results in the outcomes under investigation compared with treatment Yand does so at a lower costtreatment X would be more cost-effective. However, if treatment X produces better results but is more expensive than treatment Y, the findings may be considered ambiguous and in need of further study.
|
Collection of cost data could be part of any OMM study of clinical efficacy. However, the credibility of the cost-effectiveness aspect of a clinical trial will unavoidably depend on focused, carefully defined cost-effectiveness questions.
A first step in crafting a strong cost-effectiveness question might be to determine the economic elements included in calculating what it costs a provider to deliver a specific treatment for a specific diagnosis. This question elicits a more practical answer than the question, "What does a patient or insurance carrier pay for a specific treatment?" Payment in excess of cost may go to profit or to what economists call "economic rent,"28 both of which are important cost variables for any cost-effectiveness analysis. Economic rent, economic profit, and producer surplus are all ways of expressing the same idea; a supplier enjoys surplus when the amount that it is paid by buyers for goods exceeds the economic cost to the supplier of providing those goods. Measuring cost using data on payments that are below actual costs leaves out important economic considerations.
Researchers who study the cost-effectiveness of OMM should also give careful attention to study design and to the multivariate analysis methods they will use. In considering the use of imputed cost variables, it would be useful to apply standards and criteria from cost-effectiveness analysis in mainstream medicine and models used in socioeconomic healthcare research. Formulas must be described when proxy variables are used or costs are imputed from other variables.
We recommend that studies of the cost-effectiveness of OMM begin with simple designs in which the clinical outcomes of interest have valid and reliable sources of associated cost data. Comparisons of costs of outcomes for different medical treatments for the same condition by provider type have considerable challenges to address related to study design and methodology. These studies should be able to show that all cost data are defined in the same way and cost variables include the same elements of cost. Care should be given to the selection of the populations whose outcomes are being studied. Without clear definitions of which data are used to calculate costs, the sources used for cost data (and potential threats to the validity or reliability of the cost and clinical outcomes data), researchers may not be able to generalize the findings, and the integrity of the cost variables may be spurious.
Although a quality cost-effectiveness analysis can be simple or complex, the best cost-effectiveness studies carefully link cost data with clinical outcomes, use sound statistical methods to manage limitations of the data, and clearly communicate all actual and imputed cost variable parameters. Collaborations between OMM providers, third-party payers, biostatisticians, and healthcare economists would produce the strongest research design.
Some consideration and discussion in the OMM research sector might be given to the development of an economic model to help OMM researchers work effectively with financial managers in the design of clinical studies to identify and define essential cost variables of interest, identify reliable and valid sources for cost data, and apply contemporary methods of analysis.
All of the studies reviewed were independent of each other, and none utilized recommendations from previous studies in the area of collecting cost data or defining cost variables. Because the available information on cost-effectiveness of OMM uses limited sources of cost data or imputed costs, much work remains to be done.
Cost-effectiveness analysis of OMM is needed in many areas of disease and disability, both as an alternative for, and a complement to, conventional medical care. Although prospective cost-effectiveness studies are challenging to design and execute, those in the osteopathic medical profession cannot increase their knowledge of whether OMM is more cost-effective than other treatment modalities without concerted efforts in this area of research. Cost-effectiveness analysis of OMM must be more carefully crafted to have a favorable impact on efficient healthcare policies and to offer more choices to healthcare consumers.
From the Department of Osteopathic Manipulative Medicine, University of North Texas Health Science Center at Fort WorthTexas College of Osteopathic Medicine (Gamber), the Department of Health Management and Policy in the School of Public Health (Hilsenrath), and the Osteopathic Research Center (Cruser); the East Tennessee State University at Kingsport (Holland); and the Mayo Clinic College of Medicine in Rochester, Minn (Russo).
| References |
|---|
|
|
|---|
2. An independent analysis of claims for the Colorado workers' compensation claims. Denver, Colo: Milliman and Robertson;2001 .
3. Independent analyses of claims for the Colorado workers' compensation claims. Denver: TillinghastTowers Perrin;1996 .
4. Li Z. Texas workers' compensation medical trend analysis, 19961997. Paper presented at: Texas Workers' Compensation Program Conference; 1999.
5. Lipton JA, Meneses P, Martin JB, Mizera AC, Kappler R, Brooks JS, et al. Improved pain score outcomes achieved through the cooperative and cost-effective use of physical (osteopathic manipulative) medicine in the treatment of outpatient musculoskeletal complaints. Amer Acad Osteopath J. Spring 2002;12:2632. Available at: http://www.academyofosteopathy.org/Spring2002.pdf. Accessed August 10, 2005.
6. Cantieri MS. Inpatient osteopathic manipulative treatment; impact on length of stay. Amer Acad Osteopath J. Winter1997; 7:25 29.
7. Hess JA, Mootz RD. Comparison of work and time estimates by chiropractic physicians with those of medical and osteopathic providers. J Manipulative Physiol Ther.1999; 22:280 291.[Medline]
8. Swords WJ. Low back pain: cost and treatment. Amer Acad Osteopath J. Winter 2000;10:22 30.
9. Andersson GB, Lucente T, Davis AM, Kappler RE, Lipton JA, Leurgans S. A comparison of osteopathic spinal manipulation with standard care for patients with low back pain [published correction appears in N Engl J Med. 2000;342:817]. N Engl J Med. 1999;341:14261431. Abstract available at: http://content.nejm.org/cgi/content/abstract/341/19/1426. Accessed August 10, 2005.
10. Klock GB. The impact of osteopathic manipulative medicine on inpatient outcomes. Amer Acad Osteopath J. Spring 2002;12:3338. Available at: http://www.academyofosteopathy.org/Spring2002.pdf. Accessed August 10, 2005.
11. Radjieski JM, Lumley MA, Cantieri MS. Effect of osteopathic manipulative treatment on length of stay for pancreatitis: a randomized pilot study [published correction appears in J Am Osteopath Assoc. 1998;98:408]. J Am Osteopath Assoc.1998; 98:264 272.[Abstract]
12. Noll DR, Shores JH, Gamber RG, Herron KM, Swift J Jr. Benefits of osteopathic manipulative treatment for hospitalized elderly patients with pneumonia. J Am Osteopath Assoc. 2000;100:776782. Available at: http://www.jaoa.org/cgi/reprint/100/12/776. Accessed August 10, 2005.
13. Licciardone JC, Gamber RG, Russo DP. Quality of life in referred patients presenting to a specialty clinic for osteopathic manipulative treatment. JAm Osteopath Assoc. 2002;102:151155. Available at: http://www.jaoa.org/cgi/reprint/102/3/151. Accessed August 10, 2005.
14. Licciardone J, Gamber R, Cardarelli K. Patient satisfaction and clinical outcomes associated with osteopathic manipulative treatment. J Am Osteopath Assoc. 2002;102:1320. Available at: http://www.jaoa.org/cgi/reprint/102/1/13. Accessed August 10, 2005.
15. Gamber RG, Shores JH, Russo DP, Jimenez C, Rubin BR. Osteopathic manipulative treatment in conjunction with medication relieves pain associated with fibromyalgia syndrome: results of a randomized clinical pilot project. J Am Osteopath Assoc. 2002;102:321325. Available at: http://www.jaoa.org/cgi/reprint/102/6/321. Accessed August 10, 2005.
16. Knebl JA, Shores JH, Gamber RG, Gray WT, Herron KM. Improving functional ability in the elderly via the Spencer technique, an osteopathic manipulative treatment: a randomized, controlled trial. J Am Osteopath Assoc. 2002;102:387396. Available at: http://www.jaoa.org/cgi/reprint/102/7/387. Accessed August 10, 2005.
17. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine [review]. JAMA.1996; 276:1253 1258.[Abstract]
18. Hsiao W, Braun P, Kelly NL, Becker ER. Results, potential effects, and implementation issues of the Resource-Based Relative Value Scale. JAMA. 1988;260:2429 2438.[Abstract]
19. Assendelft WJ, Bouter LM. Does the goose really lay golden eggs? A methodological review of Workmen's Compensation studies [review]. J Manipulative Physiol Ther.1993; 16:161 168.[Medline]
20. Wolk S. An analysis of Florida workers' compensation medical claims for back-related injuries. ACA J Chiropr.1988; 27:50 59.
21. Johnson MR, Schultz MK, Ferguson AC. A comparison of chiropractic, medical and osteopathic care for work-related sprains and strains. J Manipulative Physiol Ther.1989; 12:335 344.[Medline]
22. Stano M. A comparison of health care costs for chiropractic and medical patients. J Manipulative Physiol Ther.1993; 16:291 299.[Medline]
23. Maniadakis N, Gray A. The economic burden of back pain in the UK. Pain. 2000;84:95 103.[Medline]
24. American Medical Association. ICD-9-CM 2002: International Classification of Diseases, Clinical Modification. Vols 1 and 2. 9th rev. 4th ed. Chicago, Ill: American Medical Association; 2001.
25. Hsiao WC, Braun P, Dunn DL, Becker ER, Yntema D, Verrilli DK, et al. An overview of the development and refinement of the Resource-Based Relative Value Scale: the foundation for reform of U.S. physician payment [review]. Med Care.1992; 30(11 Suppl):NS1 12.[Medline]
26. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I: Conceptual framework and item selection. Med Care. 1992;30:473 483.[Medline]
27. Ware JE Jr, Snyder MK, Wright WR, Davies AR. Defining and measuring patient satisfaction with medical care. Eval Program Plann 1983;6:247 263.[Medline]
28. Katz LK, Rosen HS, eds. Microeconomics. 3rd ed. Boston, Mass: Irwin McGraw-Hill; 1998.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |